மதிப்பு நாடகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Fourteen healthcare groups support the Value in Health Care Act
healthcarefinancenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcarefinancenews.com Daily Mail and Mail on Sunday newspapers.
Coinbase droht vorübergehender Handelsausschluss an deutschen Börsen
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
By Reuters Staff
2 Min Read
(Reuters) - U.S. activist investor ValueAct has built a stake of 5.2% in Stroeer, the German digital and outdoor advertiser said on Wednesday, following negative publicity around stock loans taken out by the company’s top investor.
Stroeer disclosed the stake, worth about $250 million as of Wednesday’s close, in a filing under German stock exchange rules requiring companies to report share holdings when they clear key thresholds - in this case a 5% barrier. ValueAct was not immediately available for comment.
Shares in Stroeer shed 10% on Feb. 22 after Manager magazine reported that CEO Udo Mueller and supervisory board member Dirk Stroeer had pledged a large number of shares as security against loans.
Hat Facebook Anzeigen Reichweite über Jahre falsch berechnet?
contentmanager.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from contentmanager.de Daily Mail and Mail on Sunday newspapers.
Carl Icahn disclossed a 7.8% stake in Bausch Health Companies in early February.
As the largest shareholder, he will leverage his position to push the company in the right direction.
Icahn joins other activist investors expecting maximum value from a business seperation transaction.
Legendary fund manager and activist investor Carl Icahn accumulated a 7.8% stake in Bausch Health Companies Inc (NYSE: BHC) and will likely leverage his status as the company’s largest shareholder to push for change.
Icahn’s stake
Icahn disclosed a 27.8 million share position in Bausch Health, formerly known as Valeant Pharmaceuticals in early February. The billionaire investor noted in a regulatory 13D filing he believes that shares are undervalued and he wants to engage in discussions with management and the board to “enhance shareholder value,” including the company’s ongoing strategic review.